Actavia Life Sciences, Inc.
RASP
$0.004
-$0.0285-87.69%
| Weiss Ratings | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -1.79 | |||
| Price History | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | 0.00% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -48.05% | |||
| 2-Year Total Return | -91.75% | |||
| 3-Year Total Return | -86.67% | |||
| 5-Year Total Return | -86.67% | |||
| 52-Week High % Change | -89.74% | |||
| 52-Week Low % Change | 150.00% | |||
| Price | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.04 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Jun 21, 2024 | |||
| 52-Week High Price (Date) | May 15, 2024 | |||
| Valuation | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.09M | |||
| Enterprise Value | 3.39M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | 0.00 | |||
| Earnings Per Share Growth | -85.90% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -1.43 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -9.82 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 771.81M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 646 396 4087 | |||
| Address | 5 Penn Plaza New York, NY 10001 | |||
| Website | www.rasna.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -427.65% | |||
| Return on Equity | -- | |||
| Income Statement | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -345.20K | |||
| Net Income (TTM) | -406.60K | |||
| Net Income Avl. to Common (TTM) | -406.60K | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 97.69% | |||
| EPS Diluted (TTM) | 0.00 | |||
| EPS Diluted Growth (Q YOY) | 98.57% | |||
| Balance Sheet | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.40K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 48.60K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -2.18M | |||
| Current Ratio (Q) | 0.022 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 48.60K | |||
| Total Current Liabilities (Q) | 2.23M | |||
| Total Debt (Q) | 304.00K | |||
| Total Liabilities (Q) | 2.23M | |||
| Total Common Equity (Q) | -2.18M | |||
| Cash Flow | RASP - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 65.70K | |||
| Net Change in Cash (TTM) | -800.00 | |||
| Levered Free Cash Flow (TTM) | 6.90K | |||
| Cash from Operations (TTM) | -66.40K | |||
